Anabolic steroids in the UK: an increasing issue for public health

References

• Abbate, V., Kicman, A.T., Evans-Brown, M., McVeigh, J., Cowan, D.A., Wilson, C., … Walker, C.J. (2015). Anabolic steroids detected in bodybuilding dietary supplements – a significant risk to public health. Drug Testing and Analysis, 7, 609–618. doi: 10.1002/dta.1728
   PubMed Web of Science ®Google Scholar
• ACMD. 2010. Advisory Council on the Misuse of Drugs, Consideration of the Anabolic Steroids. London: Home Office
   Google Scholar
• Angell, P.J., Chester, N., Sculthorpe, N., Whyte, G., George, K., & Somauroo, J. (2012). Performance enhancing drug abuse and cardiovascular risk in athletes: Implications for the clinician. British Journal of Sports Medicine, 46, 78–84. doi: 10.1136/bjsports-2012-091186
   Web of Science ®Google Scholar
• British Medical Association. (1909). Secret remedies: what they cost and what they contain. London: British Medical Association
   Google Scholar
• Backhouse, S., Collins, C., Defoort, Y., McNamee, M., Parkinson, A., & Sauer, M. (2014). Study on Doping Prevention: A map of Legal, Regulatory and Prevention Practice Provisions in EU 28. Luxembourg: Publications Office of the European Union
   Google Scholar
• Baggish, A.L., Weiner, R.B., Kanayama, G., Hudson, J.I., Picard, M.H., Hutter, A.M., & Pope, H. (2010). Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation-Heart Failure, 3, 472–U15. doi: 10.1161/Circheartfailure.109.931063
   PubMed Web of Science ®Google Scholar
• Bates, G., Jones, L., & McVeigh, J. (2014) Update of NICE Guidance PH18 Needle and Syringe Programmes (PIED Review). Liverpool: Centre for Public Health, Liverpool John Moores University
   Google Scholar
• Birtles, R., & Bellis, M. (1997). Drug services in Merseyside and Cheshire 1996: prevalence and outcomes. Liverpool: Public Health Sector, Liverpool John Moores University
   Google Scholar
• Breindahl, T., Evans-Brown, M., Hindersson, P., McVeigh, J., Bellis, M., Stensballe, A., & Kimergard, A. (2015). Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Testing and Analysis, 7, 164–172. doi: 10.1002/dta.1655
   PubMed Web of Science ®Google Scholar
• Buckley, W.E. (1988). Estimated prevalence of anabolic steroid use among male high school seniors. Journal of the American Medical Association, 260, 3441. doi: 10.1001/jama.1988.03410230059028
   PubMed Web of Science ®Google Scholar
• Chandler, M., & McVeigh, J. (2014). Steroids and image enhancing drugs 2013 survey results. Liverpool: Centre for Public Health, Liverpool John Moores University
   Google Scholar
• Choi, P.Y., & Pope, H.G. Jr (1994). Violence toward women and illicit androgenic-anabolic steroid use. Ann Clin Psychiatry, 6, 21–25
   PubMedGoogle Scholar
• Cohen, J., Collins, R., Darkes, J., & Gwartney, D. (2007). A league of their own: Demographics, motivations and patterns of use of 1955 male adult non-medical anabolic steroid users in the United States. Journal of the International Society of Sports Nutrition, 4, 12. doi: 10.1186/1550-2783-4-12
   PubMed Web of Science ®Google Scholar
• Crampin, A.C., Lamagni, T.L., Hope, V.D., Newham, J.A., Lewis, K.M., Parry, J.V., & Gill, O.N. (1998). The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. Epidemiology and Infection, 121, 381–386. doi: 10.1017/S0950268898001265
   PubMed Web of Science ®Google Scholar
• Cullen, K.J., Hope, V., Parry, J., & Ncube, F. (2015). Risk and vulnerability among people who inject image and performance enhancing drugs in England and Wales 2012–2013: Where should we focus harm reduction? In paper presented at the 24th International Harm Reduction Conference, Kuala Lumpur, Malaysia. 2015
   Google Scholar
• de Kruif, P. (1945). The Male Hormone. London: Harcourt: Brace and Company
   Google Scholar
• De Tarde, G. (1903). The laws of imitation. New York: H. Holt and Co
   Google Scholar
• Dickerman, R.D., Pertusi, R.M., Zachariah, N.Y., Dufour, D.R., & McConathy, W.J. (1999). Anabolic steroid-induced hepatotoxicity: Is it overstated? Clinical Journal of Sport Medicine, 9, 34–39. doi: 10.1097/00042752-199901000-00007
   PubMed Web of Science ®Google Scholar
• Duchaine, D. (1989). Underground steroid handbook II. Venice (CA): HLR Technical Books
   Google Scholar
• Dunn, M., McKay, F.H., & Iversen, J. (2014). Steroid users and the unique challenge they pose to needle and syringe program workers. Drug and Alcohol Review, 33, 71–77. doi: 10.1111/dar.12085
   PubMed Web of Science ®Google Scholar
• DuRant, R.H., Escobedo, L.G., & Heath, G.W. (1995). Anabolic-steroid use, strength training, and multiple-drug use among adolescents in the United-States. Pediatrics, 96, 23–28
   PubMed Web of Science ®Google Scholar
• Golub, A., Johnson, B.D., & Dunlap, E. (2005). Subcultural evolution and illicit drug use. Addiction Research & Theory, 13, 217–229. doi: 10.1080/16066350500053497
   PubMed Web of Science ®Google Scholar
• Elliot, D.L., Goldberg, L., Moe, E.L., Defrancesco, C.A., Durham, M.B., McGinnis, W, & Lockwood, C. (2008). Long-term outcomes of the ATHENA (Athletes Targeting Healthy Exercise & Nutrition Alternatives) programme for female high school athletes. Journal of Alcohol & Drug Education, 52, 73–92
   PubMedGoogle Scholar
• Evans-Brown, M., Kimergard, A., & McVeigh, J. (2009). Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market. Drug Testing and Analysis, 1, 323–326. doi: 10.1002/dta.74
   PubMed Web of Science ®Google Scholar
• Evans-Brown, M., Kimergard, A., McVeigh, J., Chandler, M., & Brandt, S.D. (2014). Bodybuilding Supplements; is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?. British Medical Journal, 348, 267–288. doi: 10.1136/bmj.g1476
   Web of Science ®Google Scholar
• Evans-Brown, M., & McVeigh, J. (2009). Injecting human growth hormone as a performance-enhancing drug-perspectives from the United Kingdom. Journal of Substance Use, 14, 267–288. doi: 10.3109/14659890903224383
   Web of Science ®Google Scholar
• Evans-Brown, M., McVeigh, J., Perkins, C., & Bellis, M. (2012). Human enhancement drugs: The emerging challenges to public health. Liverpool: North West Public Health Observatory
   Google Scholar
• Far, H.R.M., Agren, G., & Thiblin, I. (2012). Cardiac hypertrophy in deceased users of anabolic androgenic steroids: An investigation of autopsy findings. Cardiovascular Pathology, 21, 312–316. doi: 10.1016/j.carpath.2011.10.002
   PubMed Web of Science ®Google Scholar
• Ferenchick, G.S. (1996). Validity of self-report in identifying anabolic steroid use among weightlifters. Jounal of General Internal Medicine, 11, 554–556. doi: 10.1007/bf02599607
   PubMed Web of Science ®Google Scholar
• Friedle, K.E. (2000). Effects of anabolic steroids on physical health. In Yesalis, C. E. (Ed.), Anabolic steroids in sport and exercise (pp. 175–224). 2nd ed. Champaign (IL): Human Kinetics
   Google Scholar
• Fritz, M.S., MacKinnon, D.P., Williams, J., Goldberg, L., Moe, E.L., & Elliot, D.L. (2005). Analysis of baseline by treatment interactions in a drug prevention and health promotion program for high school male athletes. Addictive Behaviors, 30, 1001–1005. doi: 10.1016/j.addbeh.2004.08.030
   PubMed Web of Science ®Google Scholar
• Goldberg, L., Elliot, D.L., MacKinnon, D.P., Moe, E.L., Kuehl, K.S., Yoon, M., … Williams, J. (2007). Outcomes of a prospective trial of student-athlete drug testing: The student athlete testing using random notification (SATURN) study. Journal of Adolescent Health, 41, 421–429. doi: 10.1016/j.jadohealth.2007.08.001
   PubMed Web of Science ®Google Scholar
• Graham, M.R., Ryan, P., Baker, J.S., Davies, B., Thomas, N.E., Cooper, S.M., … Kicman, A.T. (2009). Counterfeiting in performance- and image-enhancing drugs . Drug Testing and Analysis, 1, 135. doi: 10.1002/dta.30
   PubMed Web of Science ®Google Scholar
• Henrion, R., Mandelbrot, L., & Delfieu, D. (1992). Contamination par le VIH a la suite d'injections d'anabolisants. La Presse Medicale, 21(5). PMID: 1532092
   PubMed Web of Science ®Google Scholar
• Hope, V.D., Harris, R., McVeigh, J., Cullen, K.J., Smith, J., Parry, J.V., … Ncube, F. (2016). Risk of HIV and hepatitis B and C over time among men who inject image and performance enhancing drugs in England and Wales: Results from cross-sectional prevalence surveys, 1992–2013. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 71, 331–337. doi: 10.1097/Qai.0000000000000835
   PubMed Web of Science ®Google Scholar
• Hope, V.D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., … Ncube, F. (2013). Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: A cross-sectional study. British Medical Journal, 3, e003207. doi: 10.1136/bmjopen-2013-003207
   PubMed Web of Science ®Google Scholar
• Hope, V.D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., … Ncube, F. (2015). Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiology and Infection, 143, 132–140. doi: 10.1017/S0950268814000727
   PubMed Web of Science ®Google Scholar
• Iversen, J., Topp, L., Wand, H., & Maher, L. (2013). Are people who inject performance and image-enhancing drugs an increasing population of needle and syringe program attendees? Drug and Alcohol Review, 32, 205–207. doi: 10.1111/j.1465-3362.2012.00499.x
   PubMed Web of Science ®Google Scholar
• Jalilian, F., Allahverdipour, H., Moeini, B., & Moghimbeigi, A. (2011). Effectiveness of anabolic steroid preventative intervention among gym users: Applying theory of planned behavior. Health Promot Perspect, 1, 32–40. doi: 10.5681/hpp.2011.002
   PubMedGoogle Scholar
• Johnson, M.D., Jay, M.S., Shoup, B., & Rickert, V.I. (1989). Anabolic steroid use by male adolescents . Pediatrics, 83, 921–924. doi: 10.3109/14659891.2014.911977
   PubMed Web of Science ®Google Scholar
• Kimergard, A. (2015). A qualitative study of anabolic steroid use amongst gym users in the United Kingdom: Motives, beliefs and experiences. Journal of Substance Use, 20, 288–294
   Web of Science ®Google Scholar
• Kimergard, A., Breindahl, T., Hindersson, P., & McVeigh, J. (2014a). The composition of anabolic steroids from the illicit market is largely unknown: implications for clinical case reports. Qjm-an International Journal of Medicine, 107, 597–598. doi: 10.1093/qjmed/hcu101
   PubMed Web of Science ®Google Scholar
• Kimergard, A., & McVeigh, J. (2014c). Variability and dilemmas in harm reduction for anabolic steroid users in the UK: A multi-area interview study. Harm Reduction Journal, 11, 19. doi: 10.1186/1477-7517-11-19
   PubMed Web of Science ®Google Scholar
• Kimergard, A., McVeigh, J., Knutsson, S., Breindahl, T., & Stensballe, A. (2014b). Online marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges to public health. Drug Testing and Analysis, 6, 396–398. doi: 10.1002/dta.1636
   PubMed Web of Science ®Google Scholar
• Klötz, F., Petersson, A., Hoffman, O., & Thiblin, I. (2010). The significance of anabolic androgenic steroids in a Swedish prison population. Comprehensive Psychiatry, 51, 312–318. doi: 10.1016/j.comppsych.2009.05.007
   PubMed Web of Science ®Google Scholar
• Korkia, P., Lenehan, P., & McVeigh, J. (1996). Non-medical use of androgens among women. Journal of Performance Enhancing Drugs, 1, 71
   Google Scholar
• Korkia, P., & Stimson, G.V. (1993). Anabolic Steroid Use in Great Britain: An Exploratory Investigation: Final Report to the Departments of Health for England, Scotland and Wales. London: Centre for Research on Drugs Health Behaviour
   Google Scholar
• Krieg, A., Scharhag, J., Albers, T., Kindermann, W., & Urhausen, A. (2007). Cardiac tissue Doppler in steroid users. International Journal of Sports Medicine, 28, 638–643. doi: 10.1055/s-2007-964848
   PubMed Web of Science ®Google Scholar
• Lenehan, P., Bellis, M., & McVeigh, J. (1996). A study of anabolic steroid use in the North West of England. Journal of Performance Enhancing Drugs, 1, 57–71
   Google Scholar
• Larance, B., Degenhardt, L., Copeland, J., & Dillon, P. (2008). Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug and Alcohol Review, 27, 679–686. doi: 10.1080/09595230802392568
   PubMed Web of Science ®Google Scholar
• Larance, B., Degenhardt, L., Dillon, P., & Copeland, J. (2005). Rapid assessment of performance and image enhancing drugs (PIEDs) in New South Wales: Feasibility study (Vol. Technical Report No. 239): National Drug and Alcohol Research Centre
   Google Scholar
• Lundholm, L., Käll, K., Wallin, S., & Thiblin, I. (2010). Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug and Alcohol Dependence, 111, 222–226. doi: 10.1016/j.drugalcdep.2010.04.020
   PubMed Web of Science ®Google Scholar
• Malone, D.A., Dimeff, R.J., Lombardo, J.A., & Barry Sample, R.H. (1995). Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clinical Journal of Sport Medicine, 5, 25–31. doi: 10.1097/00042752-199501000-00005
   PubMed Web of Science ®Google Scholar
• Mazur, A. (2005). Biosociology of dominance and deference. Lanham: Rowman & Littlefield Publishers
   Google Scholar
• McBride, A.J., Williamson, K., & Petersen, T. (1996). Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use. British Journal of Sports Medicine, 30, 69–70
   PubMed Web of Science ®Google Scholar
• McKillop, G., Todd, I.C., & Ballantyne, D. (1986). Increased left ventricular mass in a bodybuilder using anabolic steroids. British Journal of Sports Medicine, 20, 151–152
   PubMedGoogle Scholar
• McVeigh, J. (1996). Survey of gym owners’ opinions on the use of performance enhancing drugs. Journal of Performance Enhancing Drugs, 1, 21–24
   Google Scholar
• McVeigh, J., Bates, G., & Chandler, M. (2015). Steroids and Image Enhancing Drugs. Liverpool: Centre for Public Health: Liverpool John Moores University
   Google Scholar
• McVeigh, J., Beynon, C., & Bellis, M.A. (2003a). New challenges for agency based syringe exchange schemes: Analysis of 11 years of data (1991 to 2001) in Merseyside and Cheshire, UK. International Journal of Drug Policy, 14, 399–405. doi: 10.1016/s0955-3959(03)00141-5
   Google Scholar
• McVeigh, J., Germain, J., & Van Hout, M.C. (2016). 2, 4-Dinitrophenol, the inferno drug: A netnographic study of user experiences in the quest for leanness. Journal of Substance Use, 1–8. doi: 10.3109/14659891.2016.1149238
   Web of Science ®Google Scholar
• McVeigh, J., Hughes, K., Hounsome, J., & Bellis, M. (2003b). Over a Decade of Drug Use Epidemiology. Liverpool: Centre for Public Health, Liverpool John Moores University
   Google Scholar
• McVeigh, J., & Lenehan, P. (1994). Counterfeits and fakes: A growing problem. Relay, 1, 8–9
   Google Scholar
• Melia, P., Pipe, A., & Greenberg, L. (1996). The use of anabolic-androgenic steroids by Canadian students. Clinical Journal of Sport Medicine, 6, 9–14. doi: 10.1097/00042752-199601000-00004
   PubMed Web of Science ®Google Scholar
• MHRA. (2007). Medicines and healthcare products regulatory authority, Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007. London: Pharmaceutical Press, 4–5
   Google Scholar
• Midgley, S.J., Heather, N., Best, D., Henderson, D., McCarthy, S., & Davies, J.B. (2000). Risk behaviours for HIV and hepatitis infection among anabolic-androgenic steroid users. AIDS Care, 12, 163–170. doi: 10.1080/09540120050001832
   PubMed Web of Science ®Google Scholar
• Monaghan, L.F. (2001). Bodybuilding, drugs, and risk. London; New York: Routledge
   Google Scholar
• Musshoff, F., Daldrup, T., & Ritsch, M. (1997). Black market in anabolic steroids – Analysis of illegally distributed products. Journal of Forensic Sciences, 42, 1119–1125. doi: 10.1520/JFS14272J
   Web of Science ®Google Scholar
• NICE. (2014). Needle and syringe programmes. Retrieved from https://www.nice.org.uk/guidance/ph52/chapter/What-is-this-guidance-about
   Google Scholar
• Nilsson, S., Allebeck, P., Marklund, B., Baigi, A., & Fridlund, B. (2004). Evaluation of a health promotion programme to prevent the misuse of androgenic anabolic steroids among Swedish adolescents. Health Promotion International, 19, 61–67. doi: 10.1093/heapro/dah108
   PubMed Web of Science ®Google Scholar
• ONS. (2015). Drug Misuse: Findings from the 2014/15 Crime Survey for England and Wales. Home Office, Office for National Statistics
   Google Scholar
• ONS. (2016). Population estimates by single year of age and sex for local authorities in the UK, mid-2014. Home Office, Office for National Statistics
   Google Scholar
• Parkinson, A.B., & Evans, N.A. (2006). Anabolic androgenic steroids: A survey of 500 users. Medicine and Science in Sports and Exercise, 38, 644–651. doi: 10.1249/01.mss.0000210194.56834.5d
   PubMed Web of Science ®Google Scholar
• Parrott, A.C., Choi, P.Y.L., & Davies, M. (1994). Anabolic steroid use by amateur athletes: Effects upon psychological mood states. Journal of Sports Medicine and Physical Fitness, 34, 292–298
   PubMed Web of Science ®Google Scholar
• Perry, H. (1995). Counterfeit—fake anabolic steroids and hazards of their use. Relay, 1, 9–12
   Google Scholar
• Perry, H., & Hughes, G. (1992). A case of affective disorder associated with the misuse of ‘anabolic steroids’. British Journal of Sports Medicine, 26, 219–220
   PubMedGoogle Scholar
• Phillips, W.N. (1991). Anabolic reference guide. Golden, CO, USA: Mile High Pub
   Google Scholar
• PHW. (2016). UK steroid law. Public Health Wales. Retrieved from http://www.ipedinfo.co.uk/steroid_law.html
   Google Scholar
• Pope, H.G. (1994). Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry, 51, 375
   PubMed Web of Science ®Google Scholar
• Pope, H.G., & Katz, D.L. (1990). Homicide and near-homicide by anabolic steroid users. Journal of Clinical Psychiatry, 51, 28–31
   PubMed Web of Science ®Google Scholar
• Pope, H.G., & Katz, D.L. (1992). Psychiatric effects of anabolic-steroids. Psychiatric Annals, 22, 24–29. doi: 10.3928/0048-5713-19920101-07
   Web of Science ®Google Scholar
• Pope, H.G., Kouri, E.M., & Hudson, J.I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial. Archives of General Psychiatry, 57, 133–140. doi: 10.1001/archpsyc.57.2.133
   PubMed Web of Science ®Google Scholar
• Pope, H.G., Wood, R.I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014). Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement. Endocrine Reviews, 35, 341–375. doi: 10.1210/er.2013-1058
   PubMed Web of Science ®Google Scholar
• Rogers, E.M. (1983). Diffusion of innovations. 3rd ed. New York: The Free Press
   Google Scholar
• Rogers, E.M. (1995). Diffusion of drug abuse prevention programs: Spontaneous diffusion, agenda setting, and reinvention. In T. E. Backer, S. L. David & G. P. Soucy (Eds.), Reviewing the behavioral science knowledge base on technology transfer (Vol. 155, pp. 90–105). Rockville, MD: United States Government Printing
   Google Scholar
• Sagoe, D., Holden, G., Rise, E.N.K., Torgersen, T., Paulsen, G., Krosshaug, T., … Pallesen, S. (2016). Doping prevention through anti-doping education and practical strength training: The hercules program. Performance Enhancement & Health, 5, 24–30. doi: 10.1016/j.peh.2016.01.001
   Google Scholar
• Sagoe, D., McVeigh, J., Bjornebekk, A., Essilfie, M.S., Andreassen, C.S., & Pallesen, S. (2015). Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis. Substance Abuse Treatment Prevention and Policy, 10, 12. doi: 10.1186/s13011-015-0006-5
   PubMed Web of Science ®Google Scholar
• Sagoe, D., Molde, H., Andreassen, C.S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. Annals of Epidemiology, 24, 383–398. doi: 10.1016/j.annepidem.2014.01.009
   PubMed Web of Science ®Google Scholar
• Schulte, H.M., Hall, M.J., & Boyer, M. (1993). Domestic violence associated with anabolic steroid abuse. American Journal of Psychiatry, 150, 348
   PubMed Web of Science ®Google Scholar
• Scott, M.J., & Scott, M.J. (1989). Hiv infection associated with injections of anabolic steroids. Journal of the American Medical Association, 262, 207–208
   PubMed Web of Science ®Google Scholar
• Skarberg, K., Nyberg, F., & Engstrom, I. (2009). Multisubstance use as a feature of addiction to anabolic-androgenic steroids. European Addiction Research, 15, 99–106. doi: 10.1159/000199045
   PubMed Web of Science ®Google Scholar
• Sklarek, H.M., Mantovani, R.P., Erens, E., Heisler, D., Niederman, M.S., & Fein, A.M. (1984). Aids in a bodybuilder using anabolic steroids. New England Journal of Medicine, 311, 1701. doi: 10.1056/NEJM198412273112615
   PubMed Web of Science ®Google Scholar
• Stensballe, A., McVeigh, J., Breindahl, T., & Kimergard, A. (2015). Synthetic growth hormone releasers detected in seized drugs: New trends in the use of drugs for performance enhancement. Addiction, 110, 368–369. doi: 10.1111/add.12785
   PubMed Web of Science ®Google Scholar
• Striegel, H., Simon, P., Frisch, S., Roecker, K., Dietz, K., Dickhuth, H.H., & Ulrich, R. (2006). Anabolic ergogenic substance users in fitness-sports: A distinct group supported by the health care system. Drug and Alcohol Dependence, 81, 11–19. doi: 10.1016/j.drugalcdep.2005.05.013
   PubMed Web of Science ®Google Scholar
• Su, T.P., Pagliaro, M., Schmidt, P.J., Pickar, D., Wolkowitz, O., & Rubinow, D.R. (1993). Neuropsychiatric effects of anabolic steroids in male normal volunteers. Journal of the American Medical Association, 269, 2760–2764. doi: 10.1001/jama.269.21.2760
   PubMed Web of Science ®Google Scholar
• Thevis, M., Schrader, Y., Thomas, A., Sigmund, G., Geyer, H., & Schanzer, W. (2008). Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches. Journal of Analytical Toxicology, 32, 232–240
   PubMed Web of Science ®Google Scholar
• Walters, M.J., Ayers, R.J., & Brown, D.J. (1990). Analysis of illegally distributed anabolic-steroid products by liquid-chromatography with identity confirmation by mass-spectrometry or infra-red spectrophotometry. Journal of the Association of Official Analytical Chemists, 73, 904–926
   PubMedGoogle Scholar
• Whitfield, M., Reed, H., Harrison, B., & McVeigh, J. (2015). Integrated Monitoring System Report 2014/15. Liverpool: Centre for Public Health, Liverpool John Moores University
   Google Scholar
• WHO. (1990). Task force on methods for the regulation of male fertility: Contraceptive efficacy of testosterone-induced azoospermia in normal men. The Lancet, 336, 955–959. doi: 10.1016/0140-6736(90)92416-F
   PubMed Web of Science ®Google Scholar
• Williamson, D.J. (1993). Anabolic steroid use among students at a British college of technology. British Journal of Sports Medicine, 27, 200–201. doi: 10.1136/bjsm.27.3.200
   PubMed Web of Science ®Google Scholar
• Zinberg, N.E. (1984). Drug, set and setting. New Haven: Yale University
   Google Scholar